Sponsor Deadline
Posted: 4/30/2024

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • R01 Due Date(s): Feb. 5, Jun. 5, Oct. 5

​PAR-22-099 Expiration Date May 08, 2025

Eligibility Requirements

This FOA strongly encourages the use of the multi-PD/PI option given the required multidisciplinary expertise for developing and characterizing state-of-the-art biomimetic tissue-engineered technologies for understanding cancer pathophysiology in the context of a testable cancer research hypothesis.

Amount Description

Application budgets are limited to $400,000 Direct Costs per year. The budget should reflect the actual needs of the proposed project.

The maximum project period is 5 years. The scope of the proposed project should determine the project period.